Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Capasso, Cristian ^a   Hirvinen, Mari ^a   Garofalo, Mariangela ^a,b   Romaniuk, Dmitrii ^a   Kuryk, Lukasz ^a   Sarvela, Teea ^a   Vitale, Andrea ^c   Antopolsky, Maxim ^a   Magarkar, Aniket ^a   Viitala, Tapani ^a   Suutari, Teemu ^a   Bunker, Alex ^a   Yliperttula, Marjo ^a   Urtti, Arto ^a,d   Cerullo, Vincenzo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cancer vaccine; humanized mice; immunotherapy; melanoma; oncolytic adenovirus; oncolytic vaccine; tumor epitopes

Indexed keywords

CANCER VACCINE; DOPACHROME TAUTOMERASE; EPITOPE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOGENICITY; MELANOMA; MOUSE; MTS ASSAY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHOTON CORRELATION SPECTROSCOPY; SURFACE PLASMON RESONANCE; TUMOR IMMUNITY; VACCINATION; VIRUS INFECTIVITY; ZETA POTENTIAL;

EID: 84962920492     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1105429     Document Type: Article

References (41)

1. J.R.Bischoff, D.H.Kirn, A.Williams, C.Heise, S.Horn, M.Muna, L.Ng, J.A.Nye, A.Sampson-Johannes, A.Fattaey et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-6; PMID:8832876; http://dx.doi.org/10.1126/science.274.5286.373
2. C.Heise, T.Hermiston, L.Johnson, G.Brooks, A.Sampson-Johannes, A.Williams, L.Hawkins, D.Kirn. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6:1134-9; PMID:11017145; http://dx.doi.org/10.1038/80474
3. S.N.Zhang, I.K.Choi, J.H.Huang, J.Y.Yoo, K.J.Choi, C.O.Yun. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 2011; 19:1558-68; PMID:21468000; http://dx.doi.org/10.1038/mt.2011.29
4. M.P.Seiler, S.Gottschalk, V.Cerullo, M.Ratnayake, V.P.Mane, C.Clarke, D.J.Palmer, P.Ng, C.M.Rooney, B.Lee. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther 2007; 15:386-92; PMID:17235318; http://dx.doi.org/10.1038/sj.mt.6300029
5. V.Cerullo, S.Pesonen, I.Diaconu, S.Escutenaire, P.T.Arstila, M.Ugolini, P.Nokisalmi, M.Raki, L.Laasonen, M.Sarkioja et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297-309; PMID:20484030; http://dx.doi.org/10.1158/0008-5472.CAN-09-3567
6. V.Cerullo, I.Diaconu, L.Kangasniemi, M.Rajecki, S.Escutenaire, A.Koski, V.Romano, N.Rouvinen, T.Tuuminen, L.Laasonen et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19:1737-46; PMID:21673660; http://dx.doi.org/10.1038/mt.2011.113
7. I.K.Choi, Y.Li, E.Oh, J.Kim, C.O.Yun. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-gamma- and TNF-alpha-co-producing T cell-mediated antitumor immunity. PLoS One 2013; 8:e67512; PMID:23844018; http://dx.doi.org/10.1371/journal.pone.0067512
8. M.Hirvinen, M.Rajecki, M.Kapanen, S.Parviainen, N.Rouvinen-Lagerstrom, I.Diaconu, P.Nokisalmi, M.Tenhunen, A.Hemminki, V.Cerullo. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. Hum Gene Ther 2015; 26(3):134-44; PMID:25557131; http://dx.doi.org/10.1089/hum.2014.069
9. I.Diaconu, V.Cerullo, M.L.Hirvinen, S.Escutenaire, M.Ugolini, S.K.Pesonen, S.Bramante, S.Parviainen, A.Kanerva, A.S.Loskog et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
10. L.Liljenfeldt, L.C.Dieterich, A.Dimberg, S.M.Mangsbo, A.S.Loskog. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther 2014; 21:95-102; PMID:24481488; http://dx.doi.org/10.1038/cgt.2014.2
11. S.Pesonen, I.Diaconu, V.Cerullo, S.Escutenaire, M.Raki, L.Kangasniemi, P.Nokisalmi, G.Dotti, K.Guse, L.Laasonen et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937-47; PMID:21630267; http://dx.doi.org/10.1002/ijc.26216
12. A.Koski, L.Kangasniemi, S.Escutenaire, S.Pesonen, V.Cerullo, I.Diaconu, P.Nokisalmi, M.Raki, M.Rajecki, K.Guse et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx.doi.org/10.1038/mt.2010.161
13. M.R.Sorensen, P.J.Holst, H.Pircher, J.P.Christensen, A.R.Thomsen. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 2009; 39:2725-36; PMID:19637230; http://dx.doi.org/10.1002/eji.200939543
14. E.Nwanegbo, E.Vardas, W.Gao, H.Whittle, H.Sun, D.Rowe, P.D.Robbins, A.Gambotto. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7; PMID:15013987; http://dx.doi.org/10.1128/CDLI.11.2.351–357.2004
15. A.K.Zaiss, H.B.Machado, H.R.Herschman. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009; 108:778-90; PMID:19711370; http://dx.doi.org/10.1002/jcb.22328
16. A.Fasbender, J.Zabner, M.Chillon, T.O.Moninger, A.P.Puga, B.L.Davidson, M.J.Welsh. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997; 272:6479-89; PMID:9045673; http://dx.doi.org/10.1074/jbc.272.10.6479
17. M.W.Moore, F.R.Carbone, M.J.Bevan. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54:777-85; PMID:3261634; http://dx.doi.org/10.1016/S0092-8674(88)91043-4
18. Y.Deng, J.Gibbs, I.Bacik, A.Porgador, J.Copeman, P.Lehner, B.Ortmann, P.Cresswell, J.R.Bennink, J.W.Yewdell. Assembly of MHC class I molecules with biosynthesized endoplasmic reticulum-targeted peptides is inefficient in insect cells and can be enhanced by protease inhibitors. J Immunol 1998; 161:1677-85; PMID:9712031
19. V.Cerullo, I.Diaconu, V.Romano, M.Hirvinen, M.Ugolini, S.Escutenaire, S.L.Holm, A.Kipar, A.Kanerva, A.Hemminki. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012; 20:2076-86; PMID:22828500; http://dx.doi.org/10.1038/mt.2012.137
20. W.W.Overwijk, A.Tsung, K.R.Irvine, M.R.Parkhurst, T.J.Goletz, K.Tsung, M.W.Carroll, C.Liu, B.Moss, S.A.Rosenberg et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188:277-86; PMID:9670040; http://dx.doi.org/10.1084/jem.188.2.277
21. W.W.Overwijk, N.P.Restifo. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001; Chapter 20:Unit 20 1; PMID:18432774; http://dx.doi.org/10.1002/0471142735.im2001s39
22. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
23. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
24. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, E.Tartour, L.Zitvogel, G.Kroemer et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
25. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
26. A.S.Nigatu, S.Vupputuri, N.Flynn, B.J.Neely, J.D.Ramsey. Evaluation of cell-penetrating peptide/adenovirus particles for transduction of CAR-negative cells. J Pharm Sci 2013; 102:1981-93; PMID:23592439; http://dx.doi.org/10.1002/jps.23556
27. W.R.Heath, F.R.Carbone. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001; 1:126-34; PMID:11905820; http://dx.doi.org/10.1038/35100512
28. O.P.Joffre, E.Segura, A.Savina, S.Amigorena. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
29. X.Ma, A.Serna, R.H.Xu, L.J.Sigal. The amino acid sequences flanking an antigenic determinant can strongly affect MHC class I cross-presentation without altering direct presentation. J Immunol 2009; 182:4601-7; PMID:19342634; http://dx.doi.org/10.4049/jimmunol.0803806
30. C.Capasso, M.Garofalo, M.Hirvinen, V.Cerullo. The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 2014; 6:832-55; PMID:24549268; http://dx.doi.org/10.3390/v6020832
31. P.Wonganan, M.A.Croyle. PEGylated Adenoviruses: From Mice to Monkeys. Viruses 2010; 2:468-502; PMID:21994645; http://dx.doi.org/10.3390/v2020468
32. T.Clapp, P.Siebert, D.Chen, L.Jones Braun. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci 2011; 100:388-401; PMID:20740674; http://dx.doi.org/10.1002/jps.22284
33. K.Y.Li, A.Peers-Adams, S.J.Win, S.Scullion, M.Wilson, V.L.Young, P.Jennings, V.K.Ward, M.A.Baird, S.L.Young. Antigen Incorporated In Virus-like Particles Is Delivered to Specific Dendritic Cell Subsets That Induce An Effective Antitumor Immune Response In Vivo. J Immunother 2013; 36:11-9; PMID:23211625; http://dx.doi.org/10.1097/CJI.0b013e3182787f5e
34. H.Matsushita, M.D.Vesely, D.C.Koboldt, C.G.Rickert, R.Uppaluri, V.J.Magrini, C.D.Arthur, J.M.White, Y.S.Chen, L.K.Shea et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx.doi.org/10.1038/nature10755
35. B.M.Andersen, J.R.Ohlfest. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 2012; 325:155-64; PMID:22809568; http://dx.doi.org/10.1016/j.canlet.2012.07.012
36. S.Walter, T.Weinschenk, A.Stenzl, R.Zdrojowy, A.Pluzanska, C.Szczylik, M.Staehler, W.Brugger, P.Y.Dietrich, R.Mendrzyk et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18(8):1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
37. R.Carretero, J.M.Romero, F.Ruiz-Cabello, I.Maleno, F.Rodriguez, F.M.Camacho, L.M.Real, F.Garrido, T.Cabrera. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008; 60:439-47; PMID:18545995; http://dx.doi.org/10.1007/s00251-008-0303-5
38. H.Ito, H.Aoki, F.Kuhnel, Y.Kondo, S.Kubicka, T.Wirth, E.Iwado, A.Iwamaru, K.Fujiwara, K.R.Hess et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 2006; 98:625-36; PMID:16670388; http://dx.doi.org/10.1093/jnci/djj161
39. I.Liikanen, L.Ahtiainen, M.L.Hirvinen, S.Bramante, V.Cerullo, P.Nokisalmi, O.Hemminki, I.Diaconu, S.Pesonen, A.Koski et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21:1212-23; PMID:23546299; http://dx.doi.org/10.1038/mt.2013.51
40. Biosynthesis. Peptide Property Calculator Version 3.1. 612 East Main Street Lewisville, TX 75057 Bio-Synthesis Inc.
41. A.Kanerva, K.R.Zinn, T.R.Chaudhuri, J.T.Lam, K.Suzuki, T.G.Uil, T.Hakkarainen, G.J.Bauerschmitz, M.Wang, B.Liu et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449-58; PMID:12946318; http://dx.doi.org/10.1016/S1525-0016(03)00200-4